{"schema_version":"secwatch.filing_event.v1","accession":"0001718939-25-000019","form_type":"8-K","ticker":"IDAI","cik":"0001718939","company_name":"T Stamp Inc","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.576326+00:00","generated_at":"2026-05-27T14:50:06.907574+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"T Stamp regains compliance with Nasdaq $1.00 minimum bid price rule","bullets":["Received Nasdaq notice on Jan 23, 2025 confirming compliance with Listing Rule 5550(a)(2).","Company maintained bid price of $1.00 or greater for 11 consecutive business days (Jan 6-22, 2025).","Previously disclosed bid price deficiency letters from May 3 and Nov 5, 2024; matter now closed.","Regaining compliance removes delisting risk from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001718939-25-000019","json":"https://secwatch.observer/filing/0001718939-25-000019.json","markdown":"https://secwatch.observer/filing/0001718939-25-000019.md","text":"https://secwatch.observer/filing/0001718939-25-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1718939/000171893925000019/0001718939-25-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1718939/000171893925000019/idai-20250123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T14:50:06.907574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001140361-26-023698","ticker":"PDSB","company_name":"PDS Biotechnology Corp","filed_at":"2026-06-02T19:35:05+00:00","headline":"PDS Biotech regains Nasdaq minimum bid price compliance as of June 2, 2026","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023698","json":"https://secwatch.observer/filing/0001140361-26-023698.json","markdown":"https://secwatch.observer/filing/0001140361-26-023698.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126023698/0001140361-26-023698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126023698/ef20075449_8k.htm"},"side_by_side_evidence":null},{"accession":"0001108426-26-000030","ticker":"TXNM","company_name":"TXNM ENERGY INC","filed_at":"2026-06-01T21:54:12+00:00","headline":"TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108426-26-000030","json":"https://secwatch.observer/filing/0001108426-26-000030.json","markdown":"https://secwatch.observer/filing/0001108426-26-000030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108426/000110842626000030/0001108426-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/22767/000110842626000030/pnm-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251517","ticker":"LESL","company_name":"Leslie's, Inc.","filed_at":"2026-06-01T20:28:42+00:00","headline":"Leslie's regains Nasdaq compliance for minimum market value of publicly held shares","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251517","json":"https://secwatch.observer/filing/0001193125-26-251517.json","markdown":"https://secwatch.observer/filing/0001193125-26-251517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/0001193125-26-251517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/lesl-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039424","ticker":"RICK","company_name":"RCI HOSPITALITY HOLDINGS, INC.","filed_at":"2026-06-01T19:08:52+00:00","headline":"RCI Hospitality regains Nasdaq compliance after filing delayed Q1 10-Q","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039424","json":"https://secwatch.observer/filing/0001628280-26-039424.json","markdown":"https://secwatch.observer/filing/0001628280-26-039424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/935419/000162828026039424/0001628280-26-039424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/935419/000162828026039424/rick-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068591","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-06-01T12:00:26+00:00","headline":"FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068591","json":"https://secwatch.observer/filing/0001104659-26-068591.json","markdown":"https://secwatch.observer/filing/0001104659-26-068591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/0001104659-26-068591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001476840-26-000050","ticker":"EXFY","company_name":"Expensify, Inc.","filed_at":"2026-05-29T21:15:09+00:00","headline":"Expensify regains Nasdaq minimum bid price compliance","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001476840-26-000050","json":"https://secwatch.observer/filing/0001476840-26-000050.json","markdown":"https://secwatch.observer/filing/0001476840-26-000050.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/0001476840-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/exfy-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001178913-26-002988","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-29T11:00:25+00:00","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","event_type":"regulatory","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002988","json":"https://secwatch.observer/filing/0001178913-26-002988.json","markdown":"https://secwatch.observer/filing/0001178913-26-002988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/0001178913-26-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-243074","ticker":"MNKD","company_name":"MANNKIND CORP","filed_at":"2026-05-28T12:37:11+00:00","headline":"FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-243074","json":"https://secwatch.observer/filing/0001193125-26-243074.json","markdown":"https://secwatch.observer/filing/0001193125-26-243074.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/0001193125-26-243074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/mnkd-20260527.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}